BeiGene News | Markets Insider

Seeking Alpha 1,504d

BeiGene EPS of $0.69

Seeking Alpha 1,512d

BeiGene posts positive data from interim analysis of late-stage brukinsa leukemia study

Seeking Alpha 1,528d

BeiGene reaches primary endpoint in late-stage lung cancer trial

Seeking Alpha 1,529d

BeiGene's tislelizumab combo study shows antitumor activity in solid tumors

Benzinga 1,530d

The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight

Seeking Alpha 1,531d

Seeking Alpha Catalyst Watch

Seeking Alpha 1,532d

BeiGene's zanubrutinib fails to meet co-primary endpoints in COVID-19-related pulmonary distress

Seeking Alpha 1,541d

BeiGene names Julia Wang CFO

Seeking Alpha 1,542d

Personalis inks deal with Mapkure for BGB-3245 development

Seeking Alpha 1,548d

Chi-Med, BeiGene launches mid-stage combo study in solid tumors

Seeking Alpha 1,554d

111 inks strategic partnership with BeiGene

Seeking Alpha 1,561d

Dosing underway in BeiGene's early-stage study of HPK1 inhibitor BGB-15025

Seeking Alpha 1,566d

BeiGene's tislelizumab lung cancer sBLA accepted in China

Seeking Alpha 1,573d

BeiGene closes tislelizumab collaboration and license agreement with Novartis

Seeking Alpha 1,574d

BeiGene EPS misses by $0.47, misses on revenue

Benzinga 1,582d

The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal

Benzinga 1,588d

The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts

Seeking Alpha 1,591d

Zai Lab rated buy at Jefferies noting favorable macro factors in China

Seeking Alpha 1,602d

BeiGene's tislelizumab shows survival benefit in esophageal cancer study

Benzinga 1,604d

The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market

Seeking Alpha 1,605d

BeiGene/EUSA Pharma's Sylvant application accepted by NMPA of China

Benzinga 1,609d

The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping

Benzinga 1,610d

The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study

Benzinga 1,615d

The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges

Seeking Alpha 1,617d

BeiGene's tislelizumab + chemotherapy OK'd in China for lung cancer

Benzinga 1,618d

Why BeiGene, T2 Biosystems And Amneal Are Are Moving Today

Benzinga 1,618d

The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue

Seeking Alpha 1,619d

BeiGene, Novartis in Pact to develop tislelizumab for cancer settings

Seeking Alpha 1,619d

BeiGene, Strand Therapeutics ink immuno-oncology pact

Seeking Alpha 1,653d

BeiGene's Blincyto Ok'd in China for blood and bone marrow cancer

Seeking Alpha 1,660d

BeiGene prices secondary offering at $225/ADS

Seeking Alpha 1,660d

Baker Bros offloads shares in BeiGene

Seeking Alpha 1,672d

BeiGene's Xgeva OK'd in China for bone metastases due to cancer

Seeking Alpha 1,674d

BeiGene's tislelizumab meets OS endpoint in interim analysis of lung cancer study

Seeking Alpha 1,682d

BeiGene application for neuroblastoma drug accepted in China

InvestorPlace 1,689d

3 Biotech Stocks With Eye-Catching Pipelines

Seeking Alpha 1,716d

BioAtla amends BA3071 pact with BeiGene

InvestorPlace 1,724d

3 Reasons To Be Bullish On Biotech Giant Amgen

GlobeNewswire 1,777d

BeiGene Reports Second Quarter 2020 Financial Results

GlobeNewswire 1,778d

BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

GlobeNewswire 1,787d

Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China

GlobeNewswire 1,797d

BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

GlobeNewswire 1,799d

BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

GlobeNewswire 1,802d

BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

GlobeNewswire 1,812d

BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

GlobeNewswire 1,813d

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

GlobeNewswire 1,813d

BeiGene Announces Appointment of Angus Grant as Chief Business Executive

GlobeNewswire 1,814d

BeiGene Begins Commercializing XGEVA® (Denosumab) in China

Seeking Alpha 1,825d

BeiGene's marketing application for tislelizumab + chemotherapy in lung cancer OK'd in China

GlobeNewswire 1,826d

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

News for BeiGene Ltd (spons. ADRs)